Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7099 USD | -1.40% | -4.20% | -85.53% |
Mar. 15 | Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating | MT |
Mar. 14 | Quoin Pharmaceuticals Seeks M&A Opportunities | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 15.58M | Capitalization | 2.62M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | -9M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.17 x |
P/E ratio 2024 * |
-0.33
x | P/E ratio 2025 * |
-0.57
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 26.26% |
Latest transcript on Quoin Pharmaceuticals, Ltd.
1 day | -1.40% | ||
1 week | -4.20% | ||
Current month | -25.27% | ||
1 month | -20.24% | ||
3 months | -81.07% | ||
6 months | -82.69% | ||
Current year | -85.53% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Myers
CEO | Chief Executive Officer | 62 | 18-03-04 |
Denise Carter
FOU | Founder | 55 | 18-03-04 |
Gordon Dunn
DFI | Director of Finance/CFO | 60 | 21-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Sember
BRD | Director/Board Member | - | 21-10-27 |
Dennis Langer
BRD | Director/Board Member | 73 | 21-10-27 |
Joseph Cooper
BRD | Director/Board Member | 66 | 21-10-27 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.7099 | -1.40% | 40,768 |
24-04-18 | 0.72 | -1.79% | 10,044 |
24-04-17 | 0.7331 | +1.82% | 37,109 |
24-04-16 | 0.72 | +0.85% | 34,779 |
24-04-15 | 0.7139 | -3.66% | 81,537 |
Delayed Quote Nasdaq, April 19, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-85.53% | 2.65M | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- QNRX Stock